$TNXP NEW DATA Tonmya 🚀🚀+13.12% last week; maybe next week it will be +100%

$TNXP may be one of the most mispriced small-cap biotech launches right now.

TONMYA = 1st new fibromyalgia drug in 15+ years.

Company already reported \~4.2k cumulative scripts, \~2.5k patients started, 1.5k+ prescribers very early post-launch.

If Symphony is undercounting and the real gap is 1.5x–1.7x (unofficial theory), market may be massively underestimating demand.

Bullish YE26 setup:

💎2.2k–3.0k weekly TRx

💎$220M–$300M gross annualized run-rate

💎$160M–$230M 2027 net sales potential

🚀Bull case: $50–$75/share

🚀Blue sky: \~$90 if TONMYA becomes a true commercial winner + dilution fears fade.